Doxorubicin-induced cardiomyopathy is driven by oxidative stress and inflammation through pathways such as Nrf2/Keap1/ARE and NLRP3/caspase-1, which serve as potential therapeutic targets.
This review highlights the role of oxidative stress and inflammation signaling pathways in doxorubicin-induced cardiomyopathy, providing a theoretical basis for future cardioprotective drug research.
Abstract Doxorubicin (DOX) is a powerful and commonly used chemotherapeutic drug, used alone or in combination in a variety of cancers, while it has been found to cause serious cardiac side effects in clinical application. More and more researchers are trying to explore the molecular mechanisms of DOX-induced cardiomyopathy (DIC), in which oxidative stress and inflammation are considered to play a significant role. This review summarizes signaling pathways related to oxidative stress and inflammation in DIC and compounds that exert cardioprotective effects by acting on relevant signaling pathways, including the role of Nrf2/Keap1/ARE, Sirt1/p66Shc, Sirt1/PPAR/PGC-1α signaling pathways and NOS, NOX, Fe 2+ signaling in oxidative stress, as well as the role of NLRP3/caspase-1/GSDMD, HMGB1/TLR4/MAPKs/NF-κB, mTOR/TFEB/NF-κB pathways in DOX-induced inflammation. Hence, we attempt to explain the mechanisms of DIC in terms of oxidative stress and inflammation, and to provide a theoretical basis or new idea for further drug research on reducing DIC.
Shi et al. (Tue,) conducted a review in Doxorubicin-induced cardiomyopathy. Doxorubicin was evaluated. Doxorubicin-induced cardiomyopathy is driven by oxidative stress and inflammation through pathways such as Nrf2/Keap1/ARE and NLRP3/caspase-1, which serve as potential therapeutic targets.